Abstract Background and Objective: Inhibition of the receptor activator of nuclear factor kB
ligand (RANKL) is a therapeutic target for treatment of bone disorders associated with …

Background Receptor activator of nuclear factor-κB ligand (RANKL) is essential for
osteoclast differentiation, activation, and survival. The fully human monoclonal antibody …

Denosumab is a fully human monoclonal antibody with high affinity and specificity for human
receptor activator of nuclear factor kappa B ligand (RANKL), the principal regulator of …

Osteoporosis is an age-related systemic skeletal disease characterized by low bone mass
and microarchitectural deterioration of bone tissue, with a consequent increase in bone …

Denosumab, a fully human recombinant monoclonal antibody to the receptor activator of
nuclear factor-κB ligand (RANKL), blocks binding of RANKL to the RANK receptor, found on …

Denosumab is a fully human monoclonal antibody that has high affinity for RANK ligand
(RANKL). RANKL is the essential mediator of osteoclast formation, function and survival …

Denosumab is a fully human monoclonal antibody to receptor activator of nuclear factor
kappa-B ligand (RANKL), a cytokine member of the tumor necrosis factor family that is the …

Abstract Background and Objective Denosumab (XGEVA®; AMG 162) is a fully human IgG2
monoclonal antibody, which binds to the receptor activator of nuclear factor KB ligand …

Denosumab (anti-receptor activator of nuclear factorκB ligand [RANKL] antibody) is a novel
agent, a fully human monoclonal antibody that inhibits osteoclastic-medicated bone …

Receptor activator of nuclear factor-κB ligand (RANKL) is a cytokine essential for osteoclast
differentiation, activation, and survival. Denosumab, a human monoclonal antibody against …